0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD20 > Human CD20 / MS4A1 Full Length Protein, His Tag (insect cell)

Human CD20 / MS4A1 Full Length Protein, His Tag (insect cell)

  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    Human CD20 Full Length, His Tag, insect cell (CD0-H55Ha) is expressed from Baculovirus-Insect cells (HI5). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
    Predicted N-terminus: Met 1
  • Molecular Characterization
    Online(Met 1 - Pro 297) P11836-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 35.2 kDa. The protein migrates as 35-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >80% as determined by SDS-PAGE.

  • Formulation

    Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH 7.5 with Glycerol as protectant.

    Contact us for customized product form or formulation.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • Shipping
    This product is supplied as sterile liquid solution and shipped frozen with dry ice, please inquire the shipping cost.
SDS-PAGE
Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) SDS-PAGE gel

Human CD20 Full Length, His Tag, insect cell on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 80%.

Bioactivity-ELISA
Human CD20 Full Length, His Tag, insect cellHuman CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) ELISA bioactivity

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) with a linear range of 1-16 ng/mL (in presence of DDM and CHS) (QC tested).

Human CD20 Full Length, His Tag, insect cellHuman CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) ELISA bioactivity

Immobilized Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313-1.25 μg/mL (Routinely tested).

Human CD20 Full Length, His Tag, insect cellHuman CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) ELISA bioactivity

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) with a linear range of 2-31 ng/mL (in presence of DDM and CHS) (Routinely tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Human_FcRn_Heterodimer_Protein_SPR

Ofatumumab (Human IgG1) captured on CM5 chip via ant-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded MabThera® (Rituximab) on ProteinA Biosensor, can bind Human CD20 Full Length, His Tag, insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 6.19 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $650.00

Price(USD) : $2600.00

Price(USD) : $5700.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:20 Details
  • Number of Drugs in Clinical Trials:80 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop